SAMSUNG BIOLOGICS CO.,LTD.
Financials
Valuation Metrics
SAMSUNG BIOLOGICS CO.,LTD.'s Market Cap is ₩65.9T. At end of 2025 it was ₩78.5T. Ranked #7 of 2,405 in KR market (top 0.3%), #7 of 778 on KOSPI (top 0.9%), #1 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 0.4%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 65.87T KRW | KR#7/2,405 Sec#1/231 |
| Revenue | 4.55T KRW | KR#141/2,405 Sec#2/231 |
| Net Income | 1.98T KRW | KR#27/2,405 Sec#1/231 |
| Total Assets | 12.65T KRW | KR#100/2,405 Sec#2/231 |
| Net Assets | 8.36T KRW | KR#68/2,405 Sec#2/231 |
| Employees | 5,011 | KR#59/2,405 Sec#1/231 |
| Value | ||
| P/E | 33.13x | KR#1,348/2,405 Sec#84/231 |
| P/B | 7.86x | KR#2,332/2,405 Sec#209/231 |
| PEG | 0.61x | KR#720/2,405 Sec#45/231 |
| P/S | 14.46x | KR#2,307/2,405 Sec#177/231 |
| EV/EBITDA | 29.42x | KR#1,207/2,405 Sec#75/231 |
| FCF Yield | 1.30% | KR#1,117/2,405 Sec#81/231 |
| Profitability | ||
| ROE | 23.73% | KR#116/2,405 Sec#10/231 |
| ROA | 15.68% | KR#106/2,405 Sec#9/231 |
| Op. Margin | 50.02% | KR#11/2,405 Sec#2/231 |
| Revenue Growth | -9.64% | KR#1,908/2,405 Sec#178/231 |
| Earnings Growth | 54.31% | KR#535/2,405 Sec#36/231 |
| Financial Health | ||
| Debt Ratio | 51.31% | KR#973/2,405 Sec#114/231 |
| Total Debt | 1.33T KRW | KR#169/2,405 Sec#4/231 |
| FCF | 856.07B KRW | KR#40/2,405 Sec#1/231 |
| Cash | 288.58B KRW | KR#206/2,405 Sec#4/231 |
| Current Ratio | 1.80x | KR#975/2,405 Sec#108/231 |
| Net Debt/EBITDA | 0.46x | KR#663/2,405 Sec#40/231 |
| Performance | ||
| 1Y Return | -20.98% | KR#1,198/2,405 Sec#88/231 |
| 1M Return | 4.87% | KR#170/2,405 Sec#17/231 |
| From 52W High | -28.54% | KR#375/2,405 Sec#25/231 |
| 1Y MDD | -39.85% | KR#559/2,405 Sec#39/231 |
| Trading | ||
| Volume | 37,040 shares | KR#1,160/2,405 Sec#119/231 |
| Trading Value | 53.57B KRW | KR#45/2,405 Sec#2/231 |
| Foreign Own. | 13.14% | KR#369/2,405 Sec#25/231 |
| Per Share | ||
| EPS | 42,866 KRW | KR#20/2,405 Sec#1/231 |
| BPS | 180,638 KRW | KR#79/2,405 Sec#3/231 |
Company Info
Established in 2011, this company is a biopharmaceutical CDMO specialist that incorporated development and commercialization divisions by acquiring 100% of Samsung Bioepis shares in 2022. It operates production facilities in Songdo, Incheon, offering contract manufacturing and cell line/process development services, and currently sells 10 types of biosimilars globally. The company is expanding from antibody drug-focused CDMO to next-generation biopharmaceuticals, aiming to complete an End-to-End service system with the launch of an organoid business in 2025. Samsung Biologics is headquartered in Yeonsu-gu, Incheon.